This is a $17,964 firm-fixed-price purchase order contract awarded by the National Cancer Institute, a civilian agency, to Integrated Biotherapeutics, LLC (doing business as IBT Bio Services), a self-certified small disadvantaged business. The contract is for laboratory and testing services, with a period of performance ending on May 26, 2026. There is no set-aside designation for this award. Based on the information provided, IBT Bio Services has a history of providing biomedical research and infectious disease response services to federal agencies through both prime and subcontract awards, including work related to COVID-19, neuroblastoma, Marburg virus, and Staphylococcus aureus.
Generated 3/23/25, 12:49 AM